Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
CNY 7.43
(-9.06%)
CNY 7.43
(-9.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 84.57 Million CNY | -28.46% |
| 2022 | 118.23 Million CNY | -3.76% |
| 2021 | 122.85 Million CNY | -2.06% |
| 2020 | 125.43 Million CNY | -34.93% |
| 2019 | 192.77 Million CNY | 84.99% |
| 2018 | 104.2 Million CNY | -17.82% |
| 2017 | 126.79 Million CNY | 10.86% |
| 2016 | 114.38 Million CNY | -3.31% |
| 2015 | 118.29 Million CNY | -31.2% |
| 2014 | 171.93 Million CNY | 57.24% |
| 2013 | 109.34 Million CNY | 202.31% |
| 2012 | 36.17 Million CNY | 0.36% |
| 2011 | 36.03 Million CNY | -15.0% |
| 2010 | 42.4 Million CNY | 256.15% |
| 2009 | 11.9 Million CNY | 33.85% |
| 2008 | 8.89 Million CNY | -72.93% |
| 2007 | 32.85 Million CNY | -12.21% |
| 2006 | 37.42 Million CNY | 39.44% |
| 2005 | 26.83 Million CNY | 16.96% |
| 2004 | 22.94 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 72.76 Million CNY | -5.23% |
| 2024 Q1 | 76.78 Million CNY | -9.21% |
| 2024 Q3 | 55.53 Million CNY | -23.69% |
| 2023 FY | 84.57 Million CNY | -28.46% |
| 2023 Q4 | 84.57 Million CNY | 8.87% |
| 2023 Q1 | 90.58 Million CNY | -23.38% |
| 2023 Q2 | 76.86 Million CNY | -15.15% |
| 2023 Q3 | 77.68 Million CNY | 1.06% |
| 2022 Q2 | 89.66 Million CNY | -12.95% |
| 2022 Q1 | 102.99 Million CNY | -16.16% |
| 2022 Q3 | 99.58 Million CNY | 11.06% |
| 2022 Q4 | 118.23 Million CNY | 18.73% |
| 2022 FY | 118.23 Million CNY | -3.76% |
| 2021 Q4 | 122.85 Million CNY | -10.52% |
| 2021 Q3 | 137.29 Million CNY | 10.65% |
| 2021 Q2 | 124.07 Million CNY | 12.6% |
| 2021 Q1 | 110.19 Million CNY | -12.15% |
| 2021 FY | 122.85 Million CNY | -2.06% |
| 2020 Q4 | 125.43 Million CNY | -27.76% |
| 2020 FY | 125.43 Million CNY | -34.93% |
| 2020 Q1 | 157.33 Million CNY | -18.38% |
| 2020 Q2 | 164.73 Million CNY | 4.7% |
| 2020 Q3 | 173.63 Million CNY | 5.4% |
| 2019 Q1 | 86.42 Million CNY | -17.07% |
| 2019 FY | 192.77 Million CNY | 84.99% |
| 2019 Q3 | 163.73 Million CNY | -0.74% |
| 2019 Q4 | 192.77 Million CNY | 17.73% |
| 2019 Q2 | 164.96 Million CNY | 90.88% |
| 2018 Q3 | 90.21 Million CNY | -16.25% |
| 2018 Q1 | 95.26 Million CNY | -24.87% |
| 2018 FY | 104.2 Million CNY | -17.82% |
| 2018 Q2 | 107.71 Million CNY | 13.07% |
| 2018 Q4 | 104.2 Million CNY | 15.51% |
| 2017 Q3 | 108.82 Million CNY | 1.94% |
| 2017 Q2 | 106.75 Million CNY | 13.97% |
| 2017 Q1 | 93.67 Million CNY | -18.11% |
| 2017 Q4 | 126.79 Million CNY | 16.51% |
| 2017 FY | 126.79 Million CNY | 10.86% |
| 2016 Q3 | 105.81 Million CNY | 16.41% |
| 2016 Q4 | 114.38 Million CNY | 8.09% |
| 2016 Q1 | 92.84 Million CNY | -21.52% |
| 2016 FY | 114.38 Million CNY | -3.31% |
| 2016 Q2 | 90.89 Million CNY | -2.1% |
| 2015 Q2 | 114.04 Million CNY | -16.52% |
| 2015 FY | 118.29 Million CNY | -31.2% |
| 2015 Q4 | 118.29 Million CNY | 19.12% |
| 2015 Q3 | 99.3 Million CNY | -12.92% |
| 2015 Q1 | 136.6 Million CNY | -20.55% |
| 2014 Q2 | 148.94 Million CNY | 21.27% |
| 2014 Q3 | 178.01 Million CNY | 19.52% |
| 2014 Q4 | 171.93 Million CNY | -3.42% |
| 2014 Q1 | 122.82 Million CNY | 12.32% |
| 2014 FY | 171.93 Million CNY | 57.24% |
| 2013 Q3 | 32.26 Million CNY | 73.71% |
| 2013 Q4 | 109.34 Million CNY | 238.89% |
| 2013 Q1 | 28.87 Million CNY | -20.18% |
| 2013 FY | 109.34 Million CNY | 202.31% |
| 2013 Q2 | 18.57 Million CNY | -35.67% |
| 2012 Q3 | 37.07 Million CNY | -4.14% |
| 2012 FY | 36.17 Million CNY | 0.36% |
| 2012 Q4 | 36.17 Million CNY | -2.43% |
| 2012 Q2 | 38.67 Million CNY | -1.4% |
| 2012 Q1 | 39.22 Million CNY | 8.83% |
| 2011 Q3 | 45.95 Million CNY | 7.76% |
| 2011 FY | 36.03 Million CNY | -15.0% |
| 2011 Q4 | 36.03 Million CNY | -21.57% |
| 2011 Q1 | 40.74 Million CNY | -3.91% |
| 2011 Q2 | 42.64 Million CNY | 4.67% |
| 2010 Q1 | 12.07 Million CNY | 1.41% |
| 2010 Q4 | 42.4 Million CNY | 2.66% |
| 2010 Q3 | 41.3 Million CNY | -14.76% |
| 2010 Q2 | 48.45 Million CNY | 301.31% |
| 2010 FY | 42.4 Million CNY | 256.15% |
| 2009 Q4 | 11.9 Million CNY | 133.56% |
| 2009 Q3 | 5.09 Million CNY | -9.46% |
| 2009 Q2 | 5.62 Million CNY | -12.66% |
| 2009 Q1 | 6.44 Million CNY | -27.53% |
| 2009 FY | 11.9 Million CNY | 33.85% |
| 2008 FY | 8.89 Million CNY | -72.93% |
| 2008 Q1 | 18.06 Million CNY | -45.01% |
| 2008 Q2 | 6.75 Million CNY | -62.6% |
| 2008 Q3 | 7.37 Million CNY | 9.17% |
| 2008 Q4 | 8.89 Million CNY | 20.58% |
| 2007 Q4 | 32.85 Million CNY | 10.53% |
| 2007 Q2 | 29.34 Million CNY | 0.0% |
| 2007 FY | 32.85 Million CNY | -12.21% |
| 2007 Q3 | 29.72 Million CNY | 1.3% |
| 2006 FY | 37.42 Million CNY | 39.44% |
| 2006 Q4 | 37.42 Million CNY | 0.0% |
| 2005 FY | 26.83 Million CNY | 16.96% |
| 2004 FY | 22.94 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 9.12 Billion CNY | 99.073% |
| Zhejiang Zhenyuan Share Co., Ltd. | 974.86 Million CNY | 91.324% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 1.21 Billion CNY | 93.033% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 1.63 Billion CNY | 94.834% |
| Yifan Pharmaceutical Co., Ltd. | 3.14 Billion CNY | 97.311% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 13.22 Billion CNY | 99.36% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 762.32 Million CNY | 88.905% |
| Boai NKY Medical Holdings Ltd. | 499.66 Million CNY | 83.073% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 258.46 Million CNY | 67.276% |